An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation AJ Peniket, MC Ruiz de Elvira, G Taghipour, C Cordonnier, E Gluckman, T years; Burkitt's lymphoma 37.1%; and Hodgkin's disease 24.7% years. These outcomes are relatively poor because of the high procedure-related mortality associated with these procedures, particularly in patients with Hodgkin's disease (51.7% actuarial procedure-related mortality at 4 years). Multivariate analysis showed that for all lymphomas apart from Hodgkin's disease, status at transplantation significantly affected outcome. A matched analysis was performed: for all categories of lymphoma, OS was better for autologous than for allogeneic transplantation. Relapse rate was better in the allogeneic group for low-, intermediate-and high-grade, and lymphoblastic NHL. It was equivalent for Burkitt's lymphoma and worse in the allogeneic group for Hodgkin's disease. Allogeneic transplantation appears to be superior to autologous procedures in terms of producing a lower relapse rate. The toxicity of allogeneic procedures must however be reduced before this translates into an improvement in OS.
The use of high-dose therapy and autologous hematopoietic stem cell transplantation has become widespread in patients with lymphoma. [1] [2] [3] [4] [5] The indications for and the use of allogeneic stem cell transplantation in these patients remain poorly defined. The relatively successful use of autologous procedures has perhaps precluded widespread use of allografting such as has occurred in acute and chronic leukemia. The use of allogeneic stem cell transplantation has two main theoretical justifications. Firstly, the problems of tumor contamination from reinfused autologous bone marrow are avoided since the allogeneic hematopoietic cells are tumor-free. 6 Secondly, it has been postulated that a graft-versus-lymphoma effect (analogous to graft-versus-leukemia effect) may be of direct therapeutic value. 7, 8 The major practical problem with allogeneic transplantation is the increased treatment-related mortality in comparison to autologous transplantation. 9, 10 We here report the EBMT experience with allogeneic stem cell transplantation, principally to address two issues: is the relapse rate lower than expected with allogeneic transplantation; and do the problems with these procedures outweigh the advantages in terms of overall survival (OS)?
Subjects and methodology
The first allogeneic transplant for lymphoma reported to the EBMT was performed in 1982. We used this year as the starting point for the study. For the period between 1982 and 1998, the EBMT Lymphoma Registry held 18 908 procedures, of which 18 593 were first transplants. Of these first transplant procedures, 1483 were allogeneic transplants. The analysis was restricted to the 1185 patients receiving allogeneic stem cell transplantation as a first transplant who could be classified according to histological subtypes derived from the Working Formulation.
Patients were divided into six groups according to the histological subtype reported by the referring center: (1) Low-grade non-Hodgkin's lymphoma (NHL); (2) Intermediate-grade NHL; (3) High-grade NHL (immunoblastic subtypes); (4) Lymphoblastic lymphoma; (5) Burkitt's lymphoma; and (6) Hodgkin's disease. This histological classification followed the Working Formulation, which was the principal classification system in use during the long period under study. 11 Reclassification of these lymphomas according to the REAL system was not practical given the large number of cases involved. 12 Patient characteristics at diagnosis and transplantation were compared for the autologous and allogeneic populations using univariate and multivariate analyses. The aim of these analyses was to detect imbalances in patients' characteristics at diagnosis and transplant between the autologous and allogeneic groups which could affect outcome independently of the allogeneic or autologous nature of the procedure.
Study of outcome using controlled matched subsets
The information obtained from the first stage of the analyses was used to select the matching variables and find matches for the allogeneic population within the autologous population. The possible difference in outcome of the autologous vs the allogeneic first transplants was analyzed in a controlled matched study.
Statistical techniques
Comparisons between groups were carried out using t-tests or Mann-Whitney U-tests as necessary. The distribution of a variable in the different groups was analyzed using contingency tables. Prognostic factors were studied with the Cox regression model. The proportional hazards assumption was tested with standard graphical methods, and stratification was used when lack of proportionality of the hazards was evident.
In the first instance all analyses were run on patients for whom all possible prognostic variables were reported to the EBMT. If variables were found to be grossly nonsignificant, they were dropped from the analyses, allowing more patients to enter the model. To check that patients left out of the final analysis because of missing data in at least one prognostic factor were not in other ways different from the analyzable population, the outcome measurements, progress-free survival (PFS), relapse rate, and procedurerelated mortality (PRM) of these groups were compared with the equivalent groups of patients used in the analysis. No significant differences were found, indicating that the loss of a subset of the population because of missing data was not likely to have biased the results.
Statistical analyses were performed using Stata. Matching was carried out using a program developed for that purpose by Dr Walter Gregory. The program matched a number of variables according to rules provided by the user, which allowed for different variables to be matched with different accuracy and in a pre-established order. For example, status at transplantation was selected as the first variable to be matched and the match to be exact; age, however, was not matched exactly but within a range of 75 years. After matching was been accomplished, the program provided information on degree of matching and number of perfect matches found. The files used for matching access the records in a random order avoiding possible bias due to the underlying structure of the existing sorting order. Event-time distributions were estimated using the method of Kaplan and Meier and log-rank tests were used to detect differences in event-time distributions between the allogeneic and autologous populations in the matched analysis.
Variables
Within each histological subcategory patients were analyzed according to the following characteristics at diagnosis: age, sex, stage, presence or absence of B-symptoms, and bone marrow (BM)/CNS involvement. A record of the diagnostic LDH was available in relatively few patients and so was not included in the analysis. The patients were also analyzed in terms of the characteristics at transplantation: age, BM/CNS involvement, largest lymphoma mass at transplant, number of first line treatments, disease status at transplantation, and year of transplantation.
Disease status at transplantation was classified as follows: complete remission (CR) (total resolution of all active disease areas in response to treatment); chemosensitive (at least a 50% reduction in the cross-sectional area of nodal regions on CT scanning following chemotherapy prior to the transplantation procedure), and chemoresistant (failure to meet the criteria for chemosensitivity following chemotherapy).
Bone marrow donors were classified as HLA-identical sibling, monozygotic identical twin, HLA-identical related, HLA-identical unrelated, HLA-nonidentical related, and HLA-nonidentical unrelated.
Other information used in the analyses were the details of preparative and supportive therapy, type of conditioning treatment including total body irradiation (TBI), use of T-cell depletion, presence and grade of acute graft-versushost disease (aGvHD), and cause of death.
The major end points of analysis were OS, PFS, and time to relapse after transplantation. OS was defined as the time from transplantation until death from any cause. PFS was defined as the time from the day of transplantation until disease progression or death from any cause. Time to relapse was defined as time to disease progression with deaths without relapse being censored. The time to procedure-related mortality was defined as the time from the day of transplantation to death from a cause other than disease progression. Characteristics at the time of transplantation are outlined in Table 2 . Patients with lymphoblastic lymphoma and Burkitt's lymphoma were, in the majority of cases, transplanted in complete remission (73.8% of lymphoblastic patients and 63.1% of Burkitt's patients). Relatively few patients with low-grade lymphoma (20.8%) were transplanted in CR. The Hodgkin's disease cohort includes the highest proportion (42.4%) of patients with chemoresistant disease. Within each histological subcategory, more than 81% of all donors were HLA-identical siblings (see Table 2 ). A total of 3.4% of all donors were syngeneic, although none of this type was reported to the Registry in patients with Burkitt's lymphoma.
Results

Patient characteristics at diagnosis and transplantation of the allogeneic population
Multivariate analysis of prognostic factors affecting outcome in the allogeneic population
Patient characteristics and disease status at diagnosis and transplant were used to determine their possible effect on outcome measurements using multivariate analysis. In all types of lymphoma excluding Hodgkin's, status at transplant (classified as 1st CR, chemosensitive and chemoresistant) -had a significant effect on OS ( Table 3) . The mass at transplant significantly affected OS in lymphoblastic lymphoma. For Hodgkin's disease, lymph node involvement at transplant and lymphoma mass size at transplant were the most important factors to affect OS.
Relapse rate was also affected by status at transplant in most types of lymphoma, including Hodgkin's disease, but excluding low-grade lymphoma. Other factors, including age, also influenced relapse rate (see Table 3 ). This multivariate analysis also included the year of transplant as a variable for examination (to assess whether there was a detectable improvement in outcome in recent years): this was not found to affect the outcome significantly. 
Graft-versus-host disease
An analysis on a possible relation between a decreased relapse aGvHD was performed by including the absence or presence -and level -of aGvHD in the multivariate analysis. This analysis is preliminary since it was performed on a smaller subset of the population for which we had reliable information on aGvHD manifestation. The data available on chronic GvHD were insufficient to permit a similar analysis for this condition. It was found that high levels (3 and 4) of aGvHD had a deleterious effect on OS (n ¼ 163, HR ¼ 1.59, 95% CI: 1.08-2.33) and no effect on relapse rate, while low levels (1 and 2) of aGvHD, as opposed to the absence of aGvHD, had no effect on either outcome for low-grade NHL. A low level of aGvHD was associated with improved OS (n ¼ 87, HR ¼ 0.48, 95% CI: 0.26-0.86) and all levels of aGvHD were associated with a decrease in the relapse rate (n ¼ 100, HR ¼ 0.38, 95% CI: 0.18-0.84) for intermediate-grade NHL. High levels of aGvHD had a deleterious effect on OS (n ¼ 213, HR ¼ 1.36, 95% CI: 1.05-1.77), but were associated with improved relapse rate (HR ¼ 0.50, 95% CI: 0.39-0.91), for lymphoblastic lymphoma. For high-grade NHL, Burkitt's or Hodgkin's disease, no effect of aGvHD was seen, although a trend for low levels of aGvHD to improve OS was noted in high-grade NHL (P ¼ 0.068) and Hodgkin's (P ¼ 0.085).
Overall survival
Median OS from the date of transplant for this allogeneic population was as follows: low-grade NHL 5 years; intermediate-, high-grade NHL and lymphoblastic lymphoma 1 year; Burkitt's lymphoma 4.7. months; and Hodgkin's disease 6.8 months. Actuarial OS at 4 years was: low-grade NHL 51.1%; intermediate-grade NHL 38.3%; high-grade NHL 41.2%; lymphoblastic lymphoma 42.0% years; Burkitt's lymphoma 37.1%; and Hodgkin's disease 24.7% years.
Progression-free survival
Median PFS from the date of transplant for this allogeneic population was: low-grade NHL 1.7 years; intermediate- 
Comparison of the autologous and allogeneic populations
We compared the distribution of patient characteristics at diagnosis and transplantation in both populations. These populations were significantly different in various aspects (Table 4) . Patients subjected to allogeneic transplantation tended to have a more advanced stage at diagnosis and had received more treatment before transplantation; they were younger and tended to have more blood and marrow involvement. The situation at the time of transplantation indicated that they tended to be transplanted with a worse disease status (Table 5 ) and received TBI more often. The source of stem cells also differed, with allogeneic transplants receiving mainly BM (82.5%) rather than peripheral blood stem cells (16.8%): 53.8% of autologous transplants were carried out using peripheral blood progenitor cells. The relative proportion of allogeneic/autologous procedures according to histological subtype is shown in Table 4 . A total of 7.5% of patients reported to the EBMT undergoing transplantation procedures who could be assigned to these histological subgroups received allogeneic transplantation, with the rest undergoing autologous procedures. Only 3.3% of patients with Hodgkin's disease received allogeneic transplantation as the first transplantation procedure.
Cox regression analysis was performed on patient characteristics both at diagnosis and transplantation to determine significant prognostic factors, and in particular to examine the influence of allogeneic as opposed to autologous transplantation on outcome. This analysis was initially restricted to patients for whom complete data of possible prognostic factors had been reported to the Registry. Some of these factors were shown not to affect outcome and were dropped from the analysis. Overall, the factors that were found to have significant effects on OS PFS or relapse rate were as follows: bone marrow involvement at diagnosis, age at diagnosis, age at transplant, status at transplant, largest mass at transplant, number of first line treatments, and year of transplant. The degree or significance of their effects differed with the different histological subtypes of lymphoma. Autologous vs allogeneic transplant type also had a significant effect on the three outcome measurements, but there were interactions with year of transplant. These complications led to the decision to use the matched analysis method to examine outcome differences between allogeneic and autologous transplantation.
Matched analysis
With the information obtained through multivariate analysis, we selected the variables used to match the allogeneic to the autologous population. Matching was performed on the basis of one allogeneic patient to three autologous patients: the variables matched and degree of matching are listed in Table 6 . The matching was over 90% exact for all variables for all lymphoma types, but the quality of the matching was impaired by the amount of missing data in mass at transplant and BM involvement at diagnosis when these variables were considered to be of importance.
The log-rank analysis of end points indicated that OS was always better for autologous than for allogeneic patients (Figure 1 ; see Table 7 for numbers at risk). PFS was the same in both the autologous and allogeneic groups for low-grade and intermediate-grade NHL, but better in the autologous group for the other types of NHL and for Hodgkin's. The relapse rate was better in the allogeneic groups for low-, intermediate-and high-grade NHL and for lymphoblastic lymphoma, it was equivalent for Burkitt's lymphoma, and worse in the allogeneic group for Hodgkin's disease (Figure 1a -e; Table 7 ). Treatmentrelated mortality was always worse in the allogeneic groups (Figure 2a and b; Table 7 ).
Discussion
We report the results of 1185 allogeneic hematopoietic stem cell transplants for lymphoma reported to the EBMT Registry between 1982 and 1998. Although allogeneic transplantation is occasionally performed to treat relapse after prior autologous procedures, [13] [14] [15] this study restricted the analysis to allografts carried out as the first transplantation procedure.
We divided the patients into six subgroups according to the histology based upon the Working Formulation.
11 A reclassification, according to the REAL system, was not possible since most of the procedures in these two groups were performed prior to its introduction. 12 The results were compared with the 14 687 autologous procedures reported to the Registry for patients for whom similar histological classification was possible. The study confirms that over the last two decades, the use of autologous transplantation has been much more widespread than allogeneic transplantation as reported to the EBMT: over the same period the number of autologous procedures exceeds the number of allografts more than 10-fold. Patients with lymphoblastic lymphoma and Burkitt's lymphoma appeared most likely to receive an allograft (20% of all transplantation procedures in these two groups were allografts) and the majority of these were performed in first or second CR. The use of allografts in low-, intermediate-and high-grade NHL was relatively uncommon. In Hodgkin's disease the use of allogeneic transplantation was even less common: only 167 allograft patients reported to the EBMT compared to 4797 autologous procedures.
The rather conservative use of these procedures seems to be justified since across all histological subtypes, the reported toxic death rate is alarmingly high, particularly for Hodgkin's disease in which the actuarial treatment- related mortality at 4 years is 51.7%. The increased mortality rate of allogeneic procedures compared to autologous procedures is well-recognized and due in part to the additional immunosuppression associated with allografts and the role of GVHD. 9, 16, 17 The particularly high toxicity of Hodgkin's disease allografts may be a reflection of the disproportionately large proportion of patients with resistant disease undergoing allografts: this group of patients is known to suffer increased treatmentrelated mortality even when undergoing autologous transplantation, 16 and this problem may be potentiated by the allogeneic procedure.
The increased toxicity of allografting is largely responsible for the disappointing OS in these patients. We have attempted to compare these results with those of autologous transplantation using a matched-pair analysis. In all six histological subcategories, the actuarial OS obtained with autologous transplantation procedures is superior to that obtained with allogeneic transplantation.
Clearly, there is a fundamental problem in terms of treatment-related mortality that must be addressed as a priority in centers advocating allogeneic transplantation for lymphoma patients. If such a modality is to be pursued, then this is often in the hope that allogeneic procedures will produce a therapeutic graft-versus-lymphoma effect. 16, 18 Allogeneic transplantation also affords the benefit of having a hematopoietic stem cell source free of tumor contamination. Both of these effects lead to a theoretically lower relapse rate in lymphoma allografts. The presence of a lower relapse rate in lymphoma allografts compared to autografts was confirmed by this analysis. Previous analysis of the EBMT Registry detected a lower relapse rate in patients with lymphoblastic lymphoma. 10 This finding was confirmed by our analysis. Furthermore, allogeneic transplants produced a lower relapse rate than autologous procedures in patients with low-, intermediate-, and high-grade NHL. The superiority of allogeneic procedures in terms of relapse rate in patients with indolent lymphoma is particularly striking and has been reported by other groups. [19] [20] [21] [22] [23] [24] [25] It is not possible to determine from our analysis whether the reduced relapse rate is consequent upon a graft-versuslymphoma effect or due to the hematopoietic stem cell source being free of tumor contamination. We did, however, find some evidence that a certain degree of GvHD may be associated with a lower relapse rate in some lymphoma types. Such findings are reminiscent of wellestablished data on leukaemia patients where increased severity of GvHD is associated with a lower relapse rate. 26 Indeed, the presence of at least a degree of graft-versuslymphoma effect appears likely in allogeneic transplantation and the existence of this phenomenon is supported by the reports of success with donor lymphocyte infusions for lymphoma 27 and of putative graft-versus-lymphoma effects following nonmyeloablative therapy and HLA-mismatched bone marrow transplantation. 8 However, due to the paucity of data on acute GvHD in our subset, our results are preliminary and this issue should be further explored with a larger data set. Owing to incomplete data we were unable to analyze the influence of chronic GvHD on outcome. It is possible that the potential of the graft-versuslymphoma phenomenon may be best utilized using nonmyeloablative chemotherapy followed by allogeneic stem cell transplantation. Preliminary reports have demonstrated the successful use of such protocols in lymphoma. [28] [29] [30] [31] Such protocols may be expected to decrease the currently high toxicity of allogeneic procedures, as may the increased use of allogeneic peripheral blood stem cells. 32, 33 It remains to be seen whether low-intensity allograft protocols may be of therapeutic benefit in the challenging Table 7 Numbers at risk
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Interval from transplant setting of chemoresistant lymphoma: preliminary data suggest that the outcome of such procedures is rather poor in this cohort of patients. 28 In conclusion, the EBMT experience supports the beneficial effects of allogeneic procedures in producing a lower relapse rate than autologous transplantation in lymphoma patients. There has been, however, a disappointingly high treatment-related mortality associated with these procedures, which in this analysis more than outweighs the benefits of a lower relapse rate. Whether recent improvements in the supportive care of patients undergoing high-dose therapy will translate to a reduction in the toxic death rate great enough to permit beneficial use of allogeneic procedures remains to be seen. In the meantime, the precise role of allogeneic transplantation in lymphoma has still to be defined and autologous transplantation remains the current benchmark therapy for patients requiring high-dose therapy. 
